TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

Cancer Cell

Volumn 8, Issue 5, 2005, Pages 369-380

  Thomas, Dori A ^a   Massagué, Joan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; CYTOKINE; FAS LIGAND; GAMMA INTERFERON; GENE PRODUCT; GRANZYME A; GRANZYME B; PERFORIN; SMAD PROTEIN; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN SPECIFICITY; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME REPRESSION; GENE EXPRESSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION;

ANIMALIA;

EID: 27644457376     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2005.10.012     Document Type: Article

References (47)

1. R.J. Akhurst, and R. Derynck TGF-B signaling in cancer - a double-edged sword Trends Cell Biol. 11 2001 S44 S51
2. J.D. Altman, P.A. Moss, P.J. Goulder, D.H. Barouch, M.G. McHeyzer-Williams, J.I. Bell, A.J. McMichael, and M.M. Davis Phenotypic analysis of antigen-specific T lymphocytes Science 274 1996 94 96
3. V. Appay, and S.L. Rowland-Jones The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining J. Immunol. Methods 268 2002 9 19
4. J.N. Blattman, and P.D. Greenberg Cancer immunotherapy: a treatment for the masses Science 305 2004 200 205
5. H. Bonig, U. Banning, M. Hannen, Y.M. Kim, J. Verheyen, C. Mauz-Korholz, and D. Korholz Transforming growth factor-beta1 suppresses interleukin-15- mediated interferon-gamma production in human T lymphocytes Scand. J. Immunol. 50 1999 612 618
6. C. Chen, Y. Kang, and J. Massagué Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor B arrest program Proc. Natl. Acad. Sci. USA 98 2001 992 998
7. C. Chen, Y. Kang, P.M. Siegel, and J. Massagué E2F4/5 and p107 as Smad cofactors linking the TGFb receptor o c-myc repression Cell 110 2002 19 32
8. R. Derynck, R.J. Akhurst, and A. Balmain TGF-beta signaling in tumor suppression and cancer progression Nat. Genet. 29 2001 117 129
9. R.J. Diebold, M.J. Eis, M. Yin, I. Ormsby, G.P. Boivin, B.J. Darrow, J.E. Saffitz, and T. Doetschman Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated Proc. Natl. Acad. Sci. USA 92 1995 12215 12219
10. N. Dumont, and C. Arteaga Targeting the TGFb signaling network in human neoplasia Cancer Cell 3 2003 531 536
11. L. Genestier, S. Kasibhatla, T. Brunner, and D.R. Green Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc J. Exp. Med. 189 1999 231 239
12. L. Gorelik, and R.A. Flavell Abrogation of TGFb signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease Immunity 12 2000 171 181
13. L. Gorelik, and R.A. Flavell Immune-mediated eradication of tumors through the blockade of transforming growth factor-B signaling in T cells Nat. Med. 7 2001 1118 1122
14. L. Gorelik, and R.A. Flavell Transforming growth factor beta in T cell biology Nat. Rev. Immunol. 2 2002 46 53
15. T. Hai, and M.G. Hartman The molecular biology and nomenclature of the activating transcription factor/cAMP-responsive element binding family of transcription factors: activating transcripton factor proteins and homeostasis Gene 273 2001 1 11
16. J.W. Heusel, R.L. Wesselschmidt, S. Shresta, J.H. Russell, and T.J. Ley Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells Cell 76 1994 977 987
17. T.H. Inge, K.M. McCoy, B.M. Susskind, S.K. Barrett, G. Zhao, and H.D. Bear Immunomodulatory effects of transforming growth factor-b on T lymphocytes J. Immunol. 148 1992 3847 3856
18. Y. Kang, C.R. Chen, and J. Massagué A self-enabling TGFb response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells Mol. Cell 11 2003 915 926
19. H.O. Lee, and T.A. Ferguson Biology of FasL Cytokine Growth Factor Rev. 14 2003 325 335
20. J.J. Letterio Murine models define the role of TGFb as a master regulator of immune cell function Cytokine Growth Factor Rev. 11 2000 81 87
21. J. Lieberman, and Z. Fan Nuclear war: the granzyme A-bomb Curr. Opin. Immunol. 15 2003 553 559
22. A. Makki, G. Weidt, N.E. Blachere, L. Lefrancois, and P.K. Srivastava Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor Cancer Immun. 2 2002 4 17
23. J. Massagué, S.W. Blain, and R.S. Lo TGFbeta signaling in growth control, cancer, and heritable disorders Cell 103 2000 295 309
24. Massagué, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors. Genes Dev., in press.
25. S.C. McKarns, R.H. Schwartz, and N.E. Kaminski Smad3 is essential for TGF-b1 to suppress IL2 production and TCR-induced proliferation but not IL-2-induced proliferation J. Immunol. 172 2004 4275 4284
26. J. Pardo, S. Balkow, A. Anel, and M.M. Simon The differential contribution of granzyme A and granzyme B in cytotoxic T lymphocyte-mediated apoptosis is determined by the quality of target cells Eur. J. Immunol. 32 2002 1980 1985
27. J. Pardo, S. Balkow, A. Anel, and M.M. Simon Granzymes are essential for natural kiler cell-mediated and perf-facilitated tumor control Eur. J. Immunol. 32 2002 2881 2886
28. L.A. Penix, M.T. Sweetser, W.M. Weaver, J.P. Hoeffler, T.K. Kerppola, and C.B. Wilson The proximal regulatory element of the interferon-g promoter mediates selective expression in T cells J. Biol. Chem. 271 1996 31964 31972
29. J.D. Powell, C.G. Lerner, G.R. Ewoldt, and R.H. Schwartz The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy J. Immunol. 163 1999 6631 6639
30. J.H. Russell, and T.J. Ley Lymphocyte-mediated cytotoxicity Annu. Rev. Immunol. 20 2002 323 370
31. K.S. Schluns, and L. Leofrancois Cytokine control of memory T-cell development and survival Nat. Rev. Immunol. 3 2003 269 279
32. J. Seoane, H.V. Le, and J. Massagué Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage Nature 419 2002 729 734
33. V. Shankaran, H. Ikeda, A.T. Bruce, J.M. White, P.E. Swanson, L.J. Old, and R.D. Schreiber IFNg and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature 410 2001 1107 1111
34. Y. Shi, and J. Massagué Mechanisms of TGF-b signaling from cell membrane to the nucleus Cell 113 2003 1 20
35. P.M. Siegel, and J. Massagué Cytostatic and apoptotic actions of TGFb in homeostasis and cancer Nat. Rev. Cancer 3 2003 807 820
36. P.M. Siegel, W. Shu, and J. Massagué Mad upregulation and Id2 repression accompany transforming growth factor (TGF)-beta-mediated epithelial cell growth suppression J. Biol. Chem. 278 2003 35444 35450
37. M.J. Smyth, S.L. Strobl, H.A. Young, J.R. Ortaldo, and A.C. Ochoa Regulation of lymphokine-activated killer activity and pore forming protein gene expression in human peripheral blood CD8+ T lymphocytes J. Immunol. 146 1991 3289 3297
38. S.E.A. Street, E. Cretney, and M.J. Smyth Perforin and interferon gamma activities independently control tumor initiation, growth and metastasis Blood 97 2001 192 197
39. G. Torre-Amione, R.D. Beauchamp, H. Koeppen, B.H. Park, H. Schreiber, H.L. Moses, and D.A. Rowley A highly immunogenic tumor transfected with a murine transforming growth factor type b1 cDNA escapes immune surveillance Proc. Natl. Acad. Sci. USA 87 1990 1486 1490
40. J.A. Trapani, and M.J. Smyth Functional significance of the perforin/granzyme cell death pathway Nat. Rev. Immunol. 2 2002 735 747
41. J.A. Trapani, and V.R. Sutton Granzyme B: pro-apoptotic, antiviral and antitumor functions Curr. Opin. Immunol. 15 2003 533 543
42. S.M. Wahl, J.M. Orenstein, and W. Chen TGF-b influences life and death decisions of T lymphocytes Cytokine Growth Factor Rev. 11 2000 71 79
43. S. Wojtowicz-Praga Reversal of tumor-induced immunosuppression by TGF-b inibitors Invest. New Drugs 21 2003 21 32
44. J. Won, H. Kim, E.J. Park, Y. Hong, S.J. Kim, and Y. Yun Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor B receptor therapy Cancer Res. 59 1999 1273 1277
45. X. Xu, and G.R. Screaton MHC/peptide tetramer based studies of T cell function J. Immunol. Methods 268 2002 21 28
46. X. Yang, J.J. Letterio, R.J. Lechleider, L. Chen, R. Hayman, H. Gu, A.B. Roberts, and C. Deng Targeted disruption of SMAD3 results in impaired mcucosal immunity and diminished T cell responsiveness EMBO J. 18 1999 1280 1291
47. J.M. Yingling, K.L. Blanchard, and J.S. Sawyer Development of TGF-beta signalling inhibitors for cancer therapy Nat. Rev. Drug Discov. 3 2004 1011 1022